Work

Abstract 1855: Potent anti-tumor activity against patient CLL, MM and AML by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2021-1855

Authors: Roeland Lameris, Jurjen M. Ruben, Iris de Weerdt, Rob C. Roovers, Arnon P. Kater, Thilo A. Riedl, Victoria Iglesias, Ton Adang, Tanja D. de Gruijl, Paul W.H.I Parren, Hans J. van der Vliet

Institutions: Amsterdam University Medical Centers, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam UMC Location University of Amsterdam, Lava Therapeutics (Netherlands)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3177997717

Cites:

Cited by: 1

Related to: 10